Both the Ozempic and Wegovy labels contraindicate use in patients with a personal or family history of medullary thyroid carcinoma or with Multiple Endocrine Neoplasia syndrome type 2, and in anyone with a prior serious hypersensitivity reaction to semaglutide or any excipient in the product
Benoist CC, Wright JW, Zhu M, Appleyard SM, Wayman GA, Harding JW
Consistent with the multi-society guidance on GLP-1 receptor agonists, the new MIPS measure, ABG 45, specifically targets interventions for symptomatic gastric distension patients taking GLP-1 receptor agonists, as well as other high-risk gastric distension patients such as those with bowel obstruction, ileus, or incarcerated hernias
It is essential for virtually every organ system in the body
15 (1) e0227046